Our research area is dedicated mainly to the study and characterization of Non-Hodgkin lymphoma (NLH) of childhood. The general approach includes the analysis of molecular mechanisms of tumourigenesis with a translational approach aimed to transfer biological results from the bench to clinical trials. This includes also the study of new tumour specific markers for the diagnosis and the prognosis of various malignancies. In the last years our research focused on: microRNA and gene expression signature in pediatric T-cell lymphoblastic lymphoma; genome characterization of oncogenic activity of ALK kinase in Anaplastic Large Cell Lymphoma of childhood; minimal disseminated and minimal residual disease study.
The Following projects are ongoing:
- Genomics-driven identification of molecular mechanisms and biomarkers in pediatric follicular lymphoma by exome sequencing of tumour biopsies. The most recurrent mutations will be investigated in a larger cohort of patients including adult FL and benign hyperplasia and by integrating these data with the analysis of gene expression profiles obtained from the same set of samples.
- Genomic and proteomic characterization of exosomes in Non-Hodgkin Lymphoma of childhood from patients plasma samples, in order to establish their role in disease progression and/or resistance. Exosomes are actively released vesicles (carrying RNA, DNA and protein) that can function as inter-cellular messengers. Exosomes are particularly interesting as cancer biomarkers since they are stable carriers of genetic material and proteins from their cell of origin.
- New prognostic factors in pediatric T-cell lymphoblastic lymphoma. A cooperative international study has been recently initiated by the European Inter-group co-operation on Childhood Non-Hodgkin Lymphoma (EICNHL), to identify biological prognostic factors for a new risk stratification system for T-LBL.
- Federica Lovisa
- Enrico Gaffo
- Piero Di Battista
- Anna Garbin
- Carlotta Damanti
- Elisa Tosato
- Ilaria Gallingani
Selected PublicationsPomari E, Basso G, Bresolin S, Pillon M, Carraro E, d'Amore ES, Viola G,Frasson C, Basso K, Bonvini P, Mussolin L.. 2017. NPM-ALK expression levels identify two distinct subtypes of paediatric anaplastic large cell lymphoma.. Leukemia, 31(2):498-501.
Mussolin L, Holmes AB, Romualdi C, Sales G, D'Amore ES, Ghisi M, Pillon M, Rosolen A, Basso K.. 2014. An aberrant microRNA signature in childhood T-cell lymphoblastic lymphoma affecting CDKN1B expression, NOTCH1 and growth factor signaling pathways. Leukemia, 28(9):1909-12
Mussolin L, Damm-Welk C, Pillon M, Zimmermann M, Franceschetto G, Pulford K,Reiter A, Rosolen A, Woessmann W.. 2013. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis.. Leukemia, 27(2):416-22
Mussolin L, Pillon M, d'Amore ES, Conter V, Piglione M, Lo Nigro L, Garaventa A, Buffardi S, Aricò M, Rosolen A.. 2011. Minimal disseminated disease in high-risk Burkitt’s lymphoma identifies patients with different prognosis. J Clin Oncol, 29(13):1779-84
Mussolin L, Bonvini P, Ait-Tahar K, Pillon M, Tridello G, Buffardi S, Lombardi A, Pulford K, Rosolen A.. 2009. Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL. Leukemia, 23(2):400-2
Corso Stati Uniti, 4
Phone: +39 049 9640139
Fax: +39 049 9640101